Moreover, the use of CRISPR/Cas9 technology to edit TFRC expression levels in cancer cells has shown potential in preclinical models, suggesting that manipulating TFRC could alter tumor growth dynamics and response to therapy (39). The gene discussed is TFRC; the disease is cancer.